A Phase I Study of Lenalidomide Plus a Next Generation Anti-CD20 Antibody, Obinutuzumab, in Relapsed Indolent Lymphoma

Nathan H. Fowler, Raisa M. Pinto, Chan Yoon Cheah, Sattva S. Neelapu, Francesco Turturro, Fredrick B. Hagemeister, Jorge E. Romaguera, Michelle A Fanale, Luis E. Fayad, Sheryl G. Forbes, Janine Khan, Lei Feng, Felipe Samaniego, Loretta J. Nastoupil

Research output: Contribution to journalAbstract/Meeting Abstract

Original languageEnglish
Number of pages3
JournalBlood
Volume126
Issue number23
Publication statusPublished - 3 Dec 2015
Externally publishedYes
Event57th Annual Meeting of the American-Society-of-Hematology - Orlando, United States
Duration: 5 Dec 20158 Dec 2015

Cite this

Fowler, N. H., Pinto, R. M., Cheah, C. Y., Neelapu, S. S., Turturro, F., Hagemeister, F. B., ... Nastoupil, L. J. (2015). A Phase I Study of Lenalidomide Plus a Next Generation Anti-CD20 Antibody, Obinutuzumab, in Relapsed Indolent Lymphoma. Blood, 126(23).